Global Journal of Machine Learning and Computing

ISSN : XXXX-XXXX
Volume 1, Number 1, January, 2025

# AI-Driven Drug Discovery: Revolutionizing the Pharmaceutical Industry and Reducing Time to Market

**Ahmad Bacha[1], Noman Abid[2*]**

[1]Washington University of Science and Technology, Virginia, United States of America

[2]American National University, Virginia, United States of America

[1]abacha.student@wust.edu, [2]nomanabid12345@gmail.com



**Corresponding Author**

**Noman Abid**
nomanabid12345@gmail.com

**Article History:**
Submitted: 02-01-2025
Accepted: 14-01-2025
**Published: 23-01-2025**

**Keywords**

Artificial Intelligence (AI), Machine Learning (ML), Deep Learning (DL), Drug Discovery, Pharmaceutical Industry, Drug Design.



## ABSTRACT

Technological advancements and one of the most famous technological solutions worldwide Artificial Intelligence (AI), which can revolutionize many sectors, including the pharmaceutical sector. When quirky and temporally ineffective clinical assets are identified during this process, traditional drug discovery is being reinvented because of AI technologies. These tools facilitate the prediction of drug interactions and help in the determination of the best molecule orientations and drug candidates, among others, in record time. Artificial Intelligence in drug discovery is cutting the time taken to bring drugs to the market and the costs of R&D, thus heralding a new age in targeted, efficient treatments. This paper sets out to discuss the current uses of artificial Intelligence in drug development along with the ramifications that follow in the pharma field, as well as the future potential of the application of Intelligence in evolving the drug discovery process. Thus, this paper seeks to review case studies and highlight the benefits, main challenges and potential regulatory issues related to using AI in drug discovery and accelerating the process of delivering required medication to patients.

## INTRODUCTION

The rapid It is an important sector that deals with concentrating on the making of drugs that are needed to treat various diseases. But the path from starting with a molecule, which may one day become a drug, to the point at which that drug can be bought is a long, expensive, and unpredictable one [1]. Conventionally, it used to take about 10 to 15 years from the stage of identifying the target

for drug discovery to getting a drug ready for sale; the cost could be as high as $2.6 billion for the process. However, the reality is that to date, only a small percentage of these compounds will eventually make it through clinical trials and end up being approved drugs. This long cycle and cost are a problem for pharmaceutical firms, healthcare organizations, and consumers [2]. For the last few years, AI has proven to become one of the most transformative technologies in the drug discovery field. In recent years, AI tools, especially ML & DL techniques, are on the verge of revolutionizing pharma companies' strategies to facilitate the overall drug development process.

These technologies allow extracting information from large amounts of data, including genomic data, chem properties, and outcomes of clinical trials that could have been previously unachievable [3]. As These features have been made possible through the application of AI in drug discovery disciplines, the chances of long-term efficacy and biomarkers prediction, clinical trial modelling and de-risking, and the reduction of overall costs of preparing drugs for the market can now be done with way more precision. The general effectiveness of AI in handling large and highly diverse sets of data is especially valuable for drug discovery [4].

Specifically, unsupervised learning can easily help define the sets based on data that may require a long time to be identified as significant by a human observer, considering that machine learning can identify connections between phenomena in the early stages of drug development. They can also predict how a particular molecule will act in the organism, what side effects it may cause, and — in some cases, suggest changes to the substance that could enhance its efficiency [5]. Overcoming one of the major problems of post-genomic drug discovery, AI can provide more specific drug targets with fewer off-target side effects. AI applications and artificial intelligence in the drug discovery process have a lot of advantages that are visible in the industry at the moment [6].

This is because it can help to speed up the drug discovery process by the amount of time likely required to narrow down the candidate molecules shortlist and transport them to the clinical trial phase. Minimizing cost for failure from human trial through identifying which compounds are extremely likely to be most successful in human trials, it can assist some organizations in sparing more resources for the compounds with high probabilities of success in human trials [7]. This not only shrinks the cost for pharmaceutical companies but is also necessary for more rational distribution of the funds, which will benefit patients as the treatments are developed faster. Additionally, AI can potentially provide a more personalized type of medication. Leveraging big data of many types, including genomic records of patients and outcomes, AI can contribute to the development of individualized therapy based on the patient's profile [8].

Such a transition to precise treatments will enhance the potential benefits of the therapies and likely minimize the chances of side effects since the treatments are devised depending on the patient's genome. With help of AI, platforms are already helping to identify biomarkers that would help to build drugs in this direction. The most critical concern described is data privacy and security [9]. AI models need training data many of which are patients' health records and other personal data. It is just as important to safeguard from breaches and misuse of these datasets that feed into these AI systems as it is to implement important existing guidelines like the Health Insurance Portability and Accountability Act or HIPAA in the US or the General Data Protection Regulation or GDPR in the EU [10].

One of the problems is that the use of AI models should be transparent and interpretable. People think that many AI models, intense learning models, are often said to be black boxes, implying that decisions made cannot be explained. Such lower transparency can create issues regarding the approval of a product from the regulatory agencies, for clinicians when deciding on the best treatment for patients, and most importantly, for patients' trust [11].

The current work is also trying to enhance established methodologies for constructing more interpretable AI models through "explainable AI" (XAI). In addition, one must point out the presence of algorithmic bias. The AI models learn from experience, and if the experience collected has some form of preclusion or prejudice towards certain patients, then this model can strengthen these prejudices by enhancing them and hence be discriminative [12]. To prevent this, the data fed into such AI systems have to be progressive, including fair samples of populations that would be used during drug discovery as well as clinical trial formations. However, the potential for growth with AI in drug discovery is enormous. The data processing and analysis capability alone has started to contribute to advances in developing insights into intricate diseases, designing drugs and even slices out clinical trials. The enormous growth in the fields of AI has contributed to the pharmaceutical industry and it will perhaps reach transformative growth in the near future in terms of research on drugs and how these are tested and launched on the market [13].

This paper is going to discuss the current role of AI in drug discovery; the approaches employed; the opportunities and risks of AI in drugs development and the likely directions for the advancement and growth of the pharma industry. Consequently, the following paper seeks to give a basis for understanding the state of the art on applying AI in drug discovery and its impact in the pharma industry and the society.

ISSN : XXXX-XXXX
Volume 1, Number 1, January, 2025

## AI IN DRUG DISCOVERY: AN OVERVIEW

**Traditional Drug Discovery: A Costly and Time-Consuming Process:** The conventional drug development process involves starting with an object, which is often a gene or protein implicated with the sickness [14]. Scientists afterward look for small molecule or biologic to bind with the target and alter the disease progression. From earlier stages, it is followed by high throughput screening of potential compounds, optimization of lead compounds, and preclinical and clinical studies. Nevertheless, even in recent years, the process of molecular biology, which is developing rapidly, is still relatively low efficient. Most of the drugs that make it to laboratory testing never reach the market or don't survive once they get there because they don't work or have dangerous side effects [15].

**AI and Machine Learning Transforming Drug Discovery:** Machine learning approach in drug discovery in particular is revolutionizing this line of work. In large data sets including omics data, chemical structures, and patient outcomes, AI systems are capable of spotting probably therapeutic drugs with better efficiency than human analysts. An intrinsic capability of AI is its ability to mirror other large, intricate biological systems, and anticipate how certain molecules would engage with certain biological targets in an organism, and even estimate, the goodness of new chemical entities as medicines [16]. Machine learning can be categorized into subcategories, but deep learning has had a great amount of success in pattern recognition from big and high dimensional data. It means that researchers can now create more targeted drugs that are less likely to cause side effects, are usually more effective, and overall, greatly cut the need for trial and error in this process [17].

**Applications of AI in Drug Discovery:** The application of AI ranges broadly along the complete process of drug discovery, starting with target selection and extending through clinical trial and post-marketing use. The following are some of the primary applications of AI in the pharmaceutical industry:

**Target Identification and Validation**: The first and foremost important process that is integral to any drug discovery process is the choice of a target. AI can amplify this process as genomic, proteomic and clinical data can be mined for genes, proteins, or pathways associated with diseases [18]. AI approaches make it easy to rate the functional significance of potential targets, estimate treatment's effects on them and sort targets for experimental testing. This makes the construction of a functional model in target discovery less times-consuming and increases the likelihood of finding targets that will be amenable for drug intervention and central to disease process.

**Compound Screening and Drug Design:** Conventionally, compound screening is the process of screening thousands or millions of compounds against one biological target in a very manual, exhaustive step. AI in this case means that compound libraries can be screened and modelled using

virtual scenarios for efficiency. Current artificial intelligence strategies, when fed with existing information about chemical properties and biological activities, can estimate the interaction strength of different compounds with targeted proteins, which saves considerable time and money compared with direct screening. AI-assisted drug discovery goes further in using generative models to autonomously generate brand new molecules with the right pharmacology [19]. This can range from increasing the compound's stability, solubility as well as its bioavailability, to simple alteration of the compound to reduce toxicity. This predictive ability enables the rapid cycling through molecular designs, reducing the time spent by drug hunters in the initial phase of drug discovery [20].

Biomarker Discovery: Biomarkers have a very important role in formulation of the concept of personalized, where the doctor can identify the illness at an early stage and also prescribe the right medicine for the patient. AI technologies are involved in the discovery of new biomarkers in genomic proteomics, and clinical data sets. Overall, AI can identify these biomarkers within such datasets which can enhance patient differentiation in context to clinical trials and ultimately enhance outcomes associated with the treatments [21].

**Clinical Trial Design and Patient Recruitment:** It is also improving the prospecting and conduct of the clinical trials. Some of the ways that machine learning can help include learning of patient medical history and genetic predispositions to new treatments. AI can help in choosing biomarkers which will be effective in identifying patient's responses to therapies hence improving the trial processes [22]. Moreover, AI can help better design clinical trials with ideal endpoints selection, patients' response prediction to certain therapies, and trail sites selection. Patient recruitment is also being made easier by AI enabled databases which can help clinical trial matching according to genomic and historical data.

## BENEFITS OF AI-DRIVEN DRUG DISCOVERY

The use of Artificial Intelligence in drug discovery has a number of advantages which if embraced can revolutionized the whole pharm industry. AI is enhancing the efficiency, cutting costs, increasing success rates while also helping Pharma Company's progress towards the development of personalized medicines. These have opted to improve not only the whole procedure of creating new drugs but the conditions of patients too [23].

**Reduced Time to Market:** Where AI has a significant edge in drug discovery is reducing the overall time required to launch a new drug into the market. The usual process of drug discovery is a lengthy chain that takes more than 10 years to discover the compound and develop a commercial product. Yet, it can eliminate several phases of this process and speed up others including compound screening, optimization, and clinical trial design. In the early stage, AI models can accurately identify which

drug candidates are most probable to succeed, therefore, optimizing the effort of the researchers concentrating on the most potent compounds. It also minimizes the need to run several experiments for the mixture which is time-wasteful and resource-intensive [24]. Thus, for the pharmaceutical industry, AI can radically shorten the discovery phase and accelerate the generation of drugs to stabilize and improve patients' health in the shortest time possible compared to the efficiency of tradition methods. AI can also help in early diagnosis of biomarkers, which will also help clinical trials and drug development time lines.

**Lower Costs:** There is no doubt that putting up a drug is a very capital-intensive venture, and costs of research have been on the increase in the recent past. The estimates for average of a new drug come in at over $2.6 billion, including research costs, trials, regulatory approval, and promotion [25]. AI-based drug discovery, on the other hand, can effect-cost savings across the development process of new drugs. The virtual library of compounds is scanned through AI using desk research and can select high-performing candidates almost instantly. This eliminates the need of employing expensive laboratory experiments which would have been necessitated by the need to test each compound manually. Likewise, in relation to drug discovery, AI models can anticipate how the molecules will act in the human body the same as what animal test already determined, making it easier to bring out the clarity of a drug candidate. By showing which compounds would most likely produce valuable drugs AI aids in rejecting compounds with a lower likelihood of success, thus decreasing both wasted funds and the expense of drug development [26].

**Improved Success Rates**: The field of drug discovery can benefit greatly from the application of AI tools as its outlook, for success appears to be promising. One of the causes for the high costs of traditional drug discovery is the poor hit rate of the compounds which proceed to clinical stages. Some of the drugs that are produced do not make it to the market because they cause, what is termed as side effects or because they do not work as expected, or because the intended interaction with human physiology was not quite as assumed [27]. AI, on the other hand, can suggest which compounds are likely to work via molecular modelling and drug structure refinement according to data obtained from practice. Such solutions can utilize large data sets with genetic and clinical data to assist researchers in determining which drug candidates are more effective in each case at an earlier stage. In addition, it also be enhanced these compounds to determine their effectiveness, lessen toxicity, and minimize side effects. This has the overall effect of increasing the proportion of successful trials, slashing the number of drugs that fail during development and launching more products onto the market. AI also helps in the design and life of clinical trial by making the patient population definition more accurate, hence enhancing the clinical trials [28].

**Personalized Medicine:** Perhaps the most enticing possibility of using AI in drug discovery is to develop targeted therapies which are tailored specifically to individual patients. Thus, the concept of personalized medicine means unique approaches toward disease diagnoses and respective therapy making use of patients' genotypes, as well as their habits and setting [29]. AI can then be used to review patient's genomic data, electronic medical records, and other unique data to identifying optimal substance profiles exclusive to such groups of consumers for the application of the drug. By linking AI to genetic databases, scientists are able to discover biomarkers, which would show how a person might react to a certain medication. This makes possible offering of treatments that are more effective but have minimal chances of triggering side effects. Particularly, personalized medicine can be regarded as a great transition from 'treatment for all' concept in drugs development that are much more accurate and patient-specific [30]. Artificial based methods for drug discovery is already moving the field in the direction of precision medicine in diseases of oncology where treatments are emerging as first line that targets genetic mutations. What is more, the modern focus on individualized medicine has a great potential to transform the patient management, especially in patients with multifactorial and chronic disorders by offering the therapies that are more suitable for the patient's profiles.

## CHALLENGES AND LIMITATIONS

Despite these benefits, it is crucial to understand the following difficulties and constraints of AI in drug discovery that need to be resolved for the enhanced use of the technology within the pharmaceutical field.

**Data Quality and Availability:** AI systems require a large amount of high-quality data to provide viable predictions as they do not make their own decisions. Machine learning models do not get better than the data they have been trained on and therefore should be adept. But, the most crucial concern for data scientists is getting a hold of large data sets that include all necessary parameters and those can be specifically problematic when it comes to healthcare data since it is usually scattered, messy and stored in different systems [31]. Additionally, the AI algorithms must also draw from databases that have good sample population across ethnic diversity, gender and age. Also, in clinical trial data and patient health records availability is sometimes a problem because of the privacy regulation and patient information release laws, depriving AI models of important information. It is therefore important that there is improved data input into the AI system that is of good quality, diverse and representative of drug discovery needs [32].

**Model Interpretability:** Deep learning algorithms, more specifically, are thought of as black boxes since it is hard to decipher how they arrived at a particular decision. This lack of interpretability is a

major problem, especially if in a clinical environment the evaluations are being done by professionals who require explicit detailed explanation for their actions recommended by AI [33]. Since decisions concerning patients are being made, it would be important to understand how an AI model reached the conclusion and thus if this cannot be explained then it may hamper its usage in the healthcare facilities. The research is underway to design XAI systems that enable more transparency and understanding of the black boxes governing artificial intelligence. Nevertheless, complete interpretability is still elusive; AI developers would have to employ further improvements in order to provide the models which can be fully understood by clinicians and researchers [34].

**Ethical and Regulatory Concerns:** However, that AI is playing an increasingly active role in the drug discovery process raises various ethical and regulatory questions. Some of the main issues include: confidentiality, as well as protection of patients' information [35]. Most AI models use large volumes of patient data, often containing sensitive health information; therefore, the patient data has to be secure from theft and other unauthorized access. Moreover, all AI systems have to meet current and future privacy requirements, regional and global legislation, for example, GDPR for the European Union or HIPAA for the United States [36]. The other issue is the responsibility that we assign to AI technology. With the increase use of AI in drug discovery and clinical decisions makers, one cannot help but wonder who will be held accountable when something goes wrong? And who takes responsibility for the AI system that advises the use of a particular drug that led to the adverse reaction or no result at all? Enough work has not been done to directly solve these concerns and the integration of AI systems to healthcare will call for concerted efforts of AI developers, regulatory bodies and health care practitioners [37].

## THE FUTURE OF AI IN DRUG DISCOVERY

There are numerous potentials in the future of AI used in drug discovery that can likely pave the way for numerous other advancements in the pharma field [38].

**Enhanced Collaboration between AI and Human Experts:** Yet, despite the promise of the value which could be brought by AI to the field of drug discovery, this technology is not about to replace human insight and knowledge [39]. So instead of further automatization of the process, the future of drug discovery is best seen as improved integration of artificial intelligence with human expertise. AI will give precise analysis and suggestions to researchers and healthcare professionals and the final decision will be made by the AI-assisted professionals. Such a hybrid model of drug discovery will guarantee that the benefits of both the machine learning algorithm and human input will be utilized [40].

**Expanding Applications beyond Pharmaceuticals:** Therefore, little did the world know that the

application of AI in drug discovery is not only limited to the confines of the pharmaceutical industry. AI is extending its presence in the fields of developing biologics, vaccines, as well as personalized nutrition [41]. The applicability of AI lies in the already witnessed efficacy of AI in the development of the COVID 19 vaccine which has used techniques to identify viral proteins and conjecture potential vaccines. It is expected that the uses of AI will spread into other fields of medicine such as gene therapy, regenerative medicine, and the effectiveness of long-term management of chronic diseases [42].

**AI and Global Health:** Use of artificial intelligence in drug discovery will go a long way in improving human health especially to those in the developing nations [43]. Using artificial intelligence to accelerate drug discovery to provide inexpensive efficient solutions to medical problems may therefore address public urgent health problems including infectious and neglected tropical diseases. AI also helps in enhancing the methods of delivering treatment by selecting the best logistic channels besides ensuring that the products being sold reach the needy individuals. Therefore, the interaction between AI and humanitarian actors could ensure that the latter put into place life-saving treatments that reach all those who are in need [44].

## AI TECHNOLOGIES IN DRUG DISCOVERY

By adapting new approaches to data analysis and molecular design, AI technologies are advancing at a high-speed drug discovery process. They include machine learning therefore, on the other hand Deep Learning neural networks, each of which is instrumental in enhancing the speed of drug discovery and accuracy of the outcomes. This section will review AI technologies that are utilized as the main tools in drug discovery [45].

**Machine Learning in Drug Discovery:** Machine learning is one of the key Application of AI in drug discovery. In the same way, the progression ML algorithms evaluate data and subsequently predict on potential drug candidates. In the following part of the article, various prescriptions of ML in the drug discovery process including the identification of molecular targets, virtual screening, and compound optimization will be discussed [46].

**Deep Learning and Neural Networks:** DL is a subpart of ML and includes increased computational models such as artificial neural networks that assume the structure of the human brain. DL is especially useful in handling big data, for instance, genomic and proteomic data, and in drug discovery chores like estimating protein-ligand binding affinities or synthesizing new drug molecules [47].

## CONCLUSION

Artificial intelligence in drug discovery is lauded for its potential to transform the pharmaceutical market for the better by applying advanced techniques in drug development to produce more effective results at considerably lower costs than the presently used methods. Today, the sophisticated technologies of machine learning, deep learning, and other AI methods can help the troubled pharma sector to overcome a variety of common problems that have been slowing down the identification, designing, and development of effective therapeutic agents for years. It simultaneously reduces the time frame from identification to marketing and also increases the accuracy of treatment, making the development of targeted drugs that are genetically configured to patients. Despite that, there are a few drawbacks that have to be solved some of them are still significant, but the opportunities in that area look vast. Four main areas need to be considered and managed to help realize acceptable and ethical practices for AI in drug discovery: Data quality and reliability, model interpretability, patient privacy, and legal requirements as and when they emerge. For these challenges to be addressed, it will be necessary to make decisions made by AI systems more transparent, make datasets more inclusive and modify existing policies and regulations.

## REFERENCES

[1]. Marwaha S, Ruhl M, Shorkey P. Doubling pharma value with data science. The Boston Consulting Group. 2018 Feb.

[2]. Singh R, Arya P, Dubey SH. Artificial Intelligence in Pharmaceutics: Revolutionizing Drug Formulation and Optimization. Journal of Drug Discovery and Health Sciences. 2024 Sep 25; 1(03):138-45.

[3]. Tomar P, Srivastava S, Pandey S. Revolutionizing Crisis Management: Innovative Supply Chain Strategies for Resilient Pharmaceutical Companies.

[4]. Toussaint J, Gerard R. On the mend: revolutionizing healthcare to save lives and transform the industry. Lean enterprise institute; 2010 Jun 15.

[5]. Chen JJ, Husnain A, Cheng WW. Exploring the Trade-Off between Performance and Cost in Facial Recognition: Deep Learning versus Traditional Computer Vision. In Proceedings of SAI Intelligent Systems Conference 2023 Sep 7 (pp. 400-412). Cham: Springer Nature Switzerland.

[6]. Suri GS, Kaur G, Shinde D. Beyond boundaries: exploring the transformative power of AI in pharmaceuticals. Discover Artificial Intelligence. 2024 Nov 14; 4(1):82.

[7]. Hassan A, Ibrahim A. The Coming Quantum Computing Evolution in the Pharmaceutical Industry and Drug R&D. ResearchBerg Review of Science and Technology. 2023 Nov 26; 3(11):1-6.

[8]. Husnain A, Rasool S, Saeed A, Hussain HK. Revolutionizing pharmaceutical research: harnessing machine learning for a paradigm shift in drug discovery. International Journal of Multidisciplinary Sciences and Arts. 2023 Sep 27; 2(2):149-57.

[9]. Arif A, Khan MI, Khan A. An overview of cyber threats generated by AI. International Journal of Multidisciplinary Sciences and Arts. 2024; 3(4):67-76.

[10]. Gautam AK. Artificial Intelligence in Healthcare, Pharmaceuticals, and Surgery: Revolutionizing Medicine and Patient Care. Knowledgeable Research: A Multidisciplinary Peer-Reviewd Refereed Journal. 2023 Jun 30; 1(11):62-9.

[11]. Achilladelis B, Antonakis N. The dynamics of technological innovation: the case of the pharmaceutical industry. Research policy. 2001 Apr 1; 30(4):535-88.

[12]. Husnain A, Saeed A, Hussain A, Ahmad A, Gondal MN. Harnessing AI for early detection of cardiovascular diseases: Insights from predictive models using patient data. International Journal for Multidisciplinary Research. 2024; 6(5).

[13]. Tingle TC, Patel H, Horea I, Moreau L, Budhia S. HPR88 Revolutionizing Market Access: AI-Driven Pricing Strategies in the Pharmaceutical Industry. Value in Health. 2024 Dec 1; 27(12):S292.

[14]. Ahmad A, Husnain A, Shiwlani A, Hussain A, Gondal MN, Saeed A. Ethical and clinical implications of AI integration in cardiovascular healthcare. World Journal of Advanced Research and Reviews. 2024; 23(3):2479-501.

[15]. Barua R. Revolutionizing Medicine: Exploring Cutting-Edge Technologies in Computer-Aided Medicinal Analysis. Computer-Assisted Analysis for Digital Medicinal Imagery. 2025:365-92.

[16]. Tingle TC, Patel H, Horea I, Moreau L, Budhia S. HPR88 Revolutionizing Market Access: AI-Driven Pricing Strategies in the Pharmaceutical Industry. Value in Health. 2024 Dec 1; 27(12):S292.

[17]. Saeed A, Ahmad A, Husnain A. Harnessing AI for advancements in cardiovascular disease management and drug discovery. International Journal of Science and Research Archive. 2024; 13(1):244-9.

[18]. Kalidindi VR, Rehana S, Seethamraju SM, Nori LP. Revolutionizing Medicine: Unleashing the Power of Real-World Data and AI in Advancing Clinical Trials. Brazilian Journal of Pharmaceutical Sciences. 2024 Aug 9; 60:e23980.

[19]. Kalaimani PS, Magrey AH, Vidhya CS, Srivastava P, Manipriyanka K, Naidu RK, Mishra MR, Dar BA. Revolutionizing Medicinal Chemistry: Al Powered Drug Discovery for Faster Innovation. UTTAR PRADESH JOURNAL OF ZOOLOGY. 2023 Nov 7; 44(22):287-93.

[20]. Husnain, A., Alomari, G., & Saeed, A. AI-Driven Integrated Hardware and Software Solution for EEG-Based Detection of Depression and Anxiety.

[21]. MALKAWI R. REVOLUTIONIZING DRUG DELIVERY INNOVATION: LEVERAGING AI-DRIVEN CHATBOTS FOR ENHANCED EFFICIENCY. Int J App Pharm. 2024; 16(2):52-6.

[22]. Husnain A, Saeed A. AI-enhanced depression detection and therapy: Analyzing the VPSYC system. IRE Journals, 8 (2), 162-168 [Internet]. 2024

[23]. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature reviews Drug discovery. 2010 Mar;9(3):203-14.

[24]. Sherani AM, Khan M. AI in Clinical Practice: Current Uses and the Path Forward. Global Journal of Universal Studies. 1(1):226-45.

[25]. Hemamalini V, Tyagi AK, Vasuki P, Kumari S. Industrial Automation in Drug Discovery: The Emerging of Smart Manufacturing in Industry 5.0. InConverging Pharmacy Science and Engineering in Computational Drug Discovery 2024 (pp. 159-176). IGI Global.

[26]. Sherani AM, Qayyum MU, Khan M, Shiwlani A, Hussain HK. Transforming Healthcare: The Dual Impact of Artificial Intelligence on Vaccines and Patient Care. BULLET: Jurnal Multidisiplin Ilmu. 2024 May 27; 3(2):270-80.

[27]. Chandler Jr AD. Shaping the industrial century: The remarkable story of the evolution of the modern chemical and pharmaceutical industries. Harvard University Press; 2009 Jul 1.

[28]. Khan M, Shiwlani A, Qayyum MU, Sherani AM, Hussain HK. Revolutionizing Healthcare with AI: Innovative Strategies in Cancer Medicine. International Journal of Multidisciplinary Sciences and Arts. 2024 May 26; 3(1):316-24.

[29]. Singh PK, Sachan K, Khandelwal V, Singh S, Singh S. Role of Artificial Intelligence in Drug Discovery to Revolutionize the Pharmaceutical Industry: Resources, Methods and Applications. Recent Patents on Biotechnology. 2025 Jan;19(1):35-52.

[30]. Qayyum MU, Sherani AM, Khan M, Shiwlani A, Hussain HK. Using AI in Healthcare to Manage Vaccines Effectively. JURIHUM: Jurnal Inovasi dan Humaniora. 2024 May 27; 1(6):841-54.

[31]. Oosterwal D. Revolutionizing R&D in pharma.

[32]. Qayyum MU, Sherani AM, Khan M, Hussain HK. Revolutionizing Healthcare: The Transformative Impact of Artificial Intelligence in Medicine. BIN: Bulletin of Informatics. 2023; 1(2):71-83.

[33]. Olawale A. Leveraging Digital Transformation to Enhance Efficiency in Pharmaceutical Drug Launches.

[34]. Arif A, Khan A, Khan MI. Role of AI in Predicting and Mitigating Threats: A Comprehensive Review. JURIHUM: Jurnal Inovasi dan Humaniora. 2024; 2(3):297-311.

[35]. Talwandi NS, Khare S, Thakur P. Revolutionizing Pharmaceuticals: Harnessing Blockchain for Industry Solutions. Blockchain-Enabled Solutions for the Pharmaceutical Industry. 2025 Jan 8:19-40.

[36]. Yadav S, Singh A, Singhal R, Yadav JP. Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry. Intelligent Pharmacy. 2024 Feb 24.

[37]. Zainab H, Khan R, Khan AH, Hussain HK. REINFORCEMENT LEARNING IN CARDIOVASCULAR THERAPY PROTOCOL: A NEW PERSPECTIVE.

[38]. Asif M, Alam M, Alam Q. Future of pharmaceutical marketing in India-an extensive review. International Journal of Pharma Professional's Research (IJPPR). 2023;14(3):164-85.

[39]. Khan AH, Zainab H, Khan R, Hussain HK. Deep Learning in the Diagnosis and Management of Arrhythmias. Journal of Social Research. 2024 Dec 6; 4(1):50-66.

[40]. SRINIVASAN N. AI EMPOWERING PHARMACEUTICALS: REVOLUTIONIZING THE FUTURE OF HEALTHCARE. Applications of AI.

[41]. Khan, A. H., Zainab, H., Khan, R., & Hussain, H. K. (2024). Implications of AI on Cardiovascular Patients 'Routine Monitoring and Telemedicine. BULLET: Jurnal Multidisiplin Ilmu, 3(5), 621-637.

[42]. Haider R. The Future of Pharmaceuticals Industry 2024. J. Pharmaceutics and Pharmacology Research. 2023; 6(6).

[43]. Khan R, Zainab H, Khan AH, Hussain HK. Advances in Predictive Modeling: The Role of Artificial Intelligence in Monitoring Blood Lactate Levels Post-Cardiac Surgery. International Journal of Multidisciplinary Sciences and Arts. 2024; 3(4):140-51.

[44]. Dunne KJ, Ryan CR. How Management of Medical Costs Is Revolutionizing the Drug Industry. Def. Counsel J... 1995; 62:177.

[45]. Chahuan A, Verma A, Shekho D, and Mishra R, Awasthi A. Revolutionizing the World of Pharmaceuticals: Unleashing the Game-Changing Power of 3D Printing. Current Drug Targets. 2024 Jun 1; 25(8):513-6.

[46]. John A. Revolutionizing Pharmaceutical Science: The Transformational Role of Information Technology Systems.

[47]. Bhatt P, Singh S, Kumar V, Nagarajan K, Mishra SK, Dixit PK, and Kumar V, Kumar S. Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery. Current Artificial Intelligence. 2024 Jan; 2(1):E051223224198.